5.52
Korro Bio Inc (KRRO) 最新ニュース
Korro Bio, Inc. Experiences Revision in Stock Evaluation Amid Mixed Financial Performance - Markets Mojo
Korro Bio’s RNA Editing Ambitions Take A Hit After Trial Blowup - Finimize
Korro Bio downgraded to Perform from Outperform at Oppenheimer - MSN
What high frequency data says about Korro Bio Inc.Portfolio Profit Report & Daily Oversold Bounce Ideas - newser.com
Will Korro Bio Inc. stock benefit from automationBear Alert & Technical Analysis for Trade Confirmation - newser.com
What indicators show strength in Korro Bio Inc.Portfolio Value Report & Consistent Income Trade Recommendations - newser.com
Will Korro Bio Inc. stock deliver strong dividend growthPortfolio Performance Summary & Growth Focused Investment Plans - newser.com
What makes Korro Bio Inc. stock attractive to growth fundsJuly 2025 News Drivers & Weekly High Return Stock Forecasts - newser.com
What is the fair value of Korro Bio Inc. stock nowJuly 2025 Earnings & Reliable Volume Spike Alerts - newser.com
Korro Bio, Inc.Common Stock (NQ: KRRO - FinancialContent
Korro Bio (KRRO) Price Target Decreased by 30.76% to 66.30 - MSN
Korro Bio stock fell after missing expectations in early stage KRRO-110 trial - MSN
How to track smart money flows in Korro Bio Inc.July 2025 Catalysts & Community Consensus Stock Picks - newser.com
Why Korro Bio Inc. stock is favored by pension fundsWeekly Trend Recap & Community Trade Idea Sharing Platform - newser.com
Can Korro Bio Inc. stock hit record highs againWeekly Trade Summary & Real-Time Sentiment Analysis - newser.com
Published on: 2025-11-16 03:17:25 - newser.com
William Blair Downgrades Korro Bio (KRRO) - MSN
Will Korro Bio Inc. stock attract more institutional investorsPortfolio Performance Summary & Fast Moving Trade Plans - newser.com
Korro Bio downgraded to Neutral from Buy at Chardan - MSN
Korro Bio downgraded to Neutral from Overweight at Cantor Fitzgerald - MSN
Korro Bio downgraded to Market Perform from Strong Buy at Raymond James - MSN
Korro Bio (KRRO): Assessing Valuation After Clinical Setbacks, Layoffs, and Strategic Pivot - Yahoo Finance
Why Korro Bio (KRRO) Is Down 80.0% After Restructuring, Clinical Trial Miss, and CMO Resignation - simplywall.st
Korro Bio Inc. (KRRO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Reversal indicators forming on Korro Bio Inc. stockBuy Signal & Accurate Entry and Exit Point Alerts - newser.com
Korro Bio Stock Crashes Over 75% After-Hours On Drug Failure, Downgrades And Layoffs — Yet Retail Flags ‘Buy-The-Fear’ Setup - Stocktwits
KRRO Downgraded to Hold by Jones Trading Amidst Industry Adjustm - GuruFocus
Korro Bio’s Strategic Shift Amidst Clinical Setbacks and Financial Stability Justifies Hold Rating - TipRanks
HC Wainwright & Co. Downgrades Korro Bio (KRRO) - MSN
Healthcare Stocks Tumble As Companies Shift Strategies - Finimize
Cantor Fitzgerald downgrades Korro Bio stock to Neutral after lead asset failure - Investing.com Canada
Korro Bio Plummets To A Record Low On A Big Setback In RNA-Editing - MSN
JonesResearch downgrades Korro Bio on KRRO-110 failure - TipRanks
Backtrack to GalNAc: Korro AATD strategy Rewrite post-fizzle - BioWorld MedTech
Biotech Crashes To Record Low On RNA-Editing Failure - Investor's Business Daily
More cuts at Korro as lead drug disappoints, Novo pauses collab - FirstWord Pharma
KRRO’s Sudden Decline: Time to Re-evaluate? - StocksToTrade
Korro Bio Early Trial Results Fall Short; Stock Hits New Low - inkl
KRRO Faces Major Downgrade as RBC Capital Lowers Price Target | - GuruFocus
Korro Bio reports Q3 EPS ($1.92), consensus ($2.68) - MSN
What analysts say about Korro Bio Inc stockHealthcare Stock Analysis & What the Pros Are Saying About This Stock - earlytimes.in
Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates - MSN
大文字化:
|
ボリューム (24 時間):